Figures
- FIGURE 1
Qualitative and quantitative assessment of 68Ga-DOTA-TyI3-octreotide (DOTATOC) positron emission tomography (PET)/computed tomography (CT) in lymphangioleiomyomatosis (LAM). a) Axial thoracic CT image at the level of the carina in a patient with mild LAM (forced expiratory volume in 1 s (FEV1): 99% of predicted; diffusing capacity of the lung for carbon monoxide (DLCO): 88% of predicted) demonstrates occasional scattered thin-walled cysts. c) No increased tracer uptake evident on the axial fused 68Ga-DOTATOC PET/CT image (maximum standardised uptake value (SUVmax) window range 0–5). b) A separate patient with severe LAM (FEV1: 36% of predicted; DLCO: 25% of predicted) has innumerable cysts demonstrated on this axial thoracic CT image at the level of the aortic arch. d) No increased pulmonary tracer uptake evident on 68Ga-DOTATOC PET/CT. Dashed line: sample region of interest demonstrated on PET images panels c and d. e) Semiquantitative SUVmax measures of pulmonary 68Ga-DOTATOC uptake in lungs of patients with LAM and controls. f) Target to background ratio for each lobe calculated by dividing the lobar SUVmax by the mediastinal blood pool SUVmax in lungs of patients with LAM and controls. Each dot represents an individual patient. Data are presented as mean±sd. LAM, n=4; control; n=4. ns: nonsignificant. *: p<0.05, unpaired Student's t-test.
